Immunostimulatory potential and proteome profiling of Leishmania donovani soluble exogenous antigens. (July 2015)

• Record Type: Journal Article
• Authors: Kumar, A.; Samant, M.; Misra, P.; Khare, P.; Sundar, S.; Garg, Ravendra; Dube, A.
• Is Part Of: Parasite immunology. Volume 37:Number 7(2015:Jul.)
• Page Start: 368
• Page End: 375
• Publication Date: 2015-07
• Subjects: Veterinary parasitology -- Immunological aspects -- Periodicals; Host-parasite relationships -- Immunological aspects -- Periodicals; 571.96
• DOI: 10.1111/pim.12189
• Languages: English
• ISSNs: 0141-9838

Abstract

<abstract abstract-type="main" id="pim12189-abs-0001"> <title>Summary</title> <p>Isolation of the soluble exogenous antigens (SEAgs), its immune response study and proteome profiling is an essential prerequisite for understanding the molecular pathogenesis of <italic>Leishmania donovani</italic>. The immunostimulatory potential of <italic>L. donovani </italic>SEAgs, purified from culture of <italic>L. donovani</italic> clinical isolate, was evaluated for their ability to induce cellular responses in treated/cured hamsters. SEAgs induced significant proliferative responses in lymphocytes (SI 5·6 ± 2·3; <italic>P</italic> < 0·01) isolated from cured hamster. In addition, significant NO production in response to SEAgs was also noticed in macrophages of hamsters, mouse and human cell lines (J774A‐1 and THP1). Western blot analyses with antibodies against proteophosphoglycan (PPG; surface‐expressed and secreted molecule) of <italic>L</italic>. <italic>donovani</italic> revealed that PPG molecules are also present in <italic>L. donovani </italic>SEAgs. Mass spectrometry (MS)‐based proteome analysis of 12 protein bands of SEAgs through MALDI‐TOF/TOF endorsed the identification of some Th1‐stimulatory immunogenic proteins. These immunogenic proteins may offer increased hope for the discovery of new promising vaccine candidates against visceral leishmaniasis (VL). The overall results suggest that immunostimulatory molecules are present in the SEAgs, which may be further exploited, for developing a subunit vaccine against VL a fatal human disease.</p> </abstract>